Firefly Neuroscience, Inc.: Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
Firefly Neuroscience (NASDAQ: AIFF) said TMS center customer clinical assessments using its FDA 510(k)-cleared AI-powered EEG/ERP platform Evoke rose about 291% year over year, nearly four-fold. The company said Evoke combines qEEG and ERP to support clinician assessment of conditions including depression, anxiety, and ADHD, including monitoring before, during, and after TMS.
How this was made
The 30-second read
Why it matters
The company highlights a sharp YoY increase in TMS center customer clinical assessments, positioning it as evidence of expanding adoption and more individualized TMS treatment monitoring.
Market read
AIFF’s disclosed 291% YoY increase in TMS center assessments is a fresh adoption datapoint that can move sentiment, but the absence of financial metrics limits conviction.
What to watch
The release lacks absolute scan volumes, number of TMS centers/customers, pricing, and whether the metric is recurring; traders may discount the signal without those details.
Background
Firefly’s Evoke is an FDA 510(k)-cleared AI-powered EEG/ERP platform used to support diagnostic and treatment monitoring, including in TMS center settings.
Ticker impact
Firefly reports a 291% year-over-year increase in TMS center customer clinical assessments using its FDA-cleared Evoke EEG/ERP platform.
Mild-to-moderate positive bias for AIFF, with follow-through likely dependent on whether the company provides additional revenue, customer count, or retention details in future updates.
This is a concrete growth datapoint (291% YoY) tied to a specific product and use case, but it is not accompanied by financial figures (revenue, bookings, margins) or guidance, limiting magnitude and durability of the impact.
Market effects
Reinforces the narrative that AI-assisted neurodiagnostics are gaining traction in clinical workflows, potentially improving sentiment toward EEG/ERP and digital health tools.
No clear regional read-through beyond US clinical adoption messaging.
Limited direct global impact because the metric is specifically about US TMS center customer assessments.
Counterpoint
A large percentage increase may reflect a low base or changes in reporting/engagement, so it may not translate into proportional revenue growth.
Key entities
- companyFirefly Neuroscience, Inc.
NASDAQ-listed AI neurodiagnostics company reporting growth in TMS center usage of its Evoke platform.
- productEvoke (FDA 510(k)-cleared AI-powered EEG/ERP platform)
Firefly system used for qEEG and ERP brain activity assessments to support clinical decision-making.
- customer settingTranscranial Magnetic Stimulation (TMS) centers
Clinical environment where Evoke scans are used before, during, and after care.
